pd 173074 has been researched along with Carcinoma, Anaplastic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Luan, H | 1 |
| Xu, Y | 1 |
| Fu, T | 1 |
| Luan, Y | 1 |
| Yuan, C | 1 |
| St Bernard, R | 1 |
| Zheng, L | 1 |
| Liu, W | 1 |
| Winer, D | 1 |
| Asa, SL | 1 |
| Ezzat, S | 1 |
| Büchler, P | 1 |
| Reber, HA | 1 |
| Roth, MM | 1 |
| Shiroishi, M | 1 |
| Friess, H | 1 |
| Hines, OJ | 1 |
3 other studies available for pd 173074 and Carcinoma, Anaplastic
| Article | Year |
|---|---|
[FGFR1 selective inhibitor PD173074 can reduce proliferation and induce apoptosis of nasopharyngeal carcinoma].
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Caspase 3; Cell Line, Tumor; Cell Proliferation; Humans | 2014 |
Fibroblast growth factor receptors as molecular targets in thyroid carcinoma.
Topics: Adenoviridae; Animals; Blotting, Western; Carcinoma; Cell Differentiation; Cell Line; Cell Line, Tum | 2005 |
Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Carcinoma; Cell Cycle; Cell Divi | 2007 |